BioSpace News Archive

Phase 2 study finds addition of nutritional protocol to standard of care reduces recovery time to 6.6 days from 9.3 in mild-to-moderate COVID-19 patients LOS ANGELES--( BUSINESS WIRE )-- ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19” were published on the open access preprint publication server medRxiv.org . The Phase 2 study rep

Robust pipeline of 20+ development programs across 7 rare disease franchises with future plans to continue growing pipeline with >5 novel INDs by 2025

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the formation of the Company’s Scientific Advisory Board with three leading oncology experts.

Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced preliminary unaudited revenue for the first quarter of its fiscal year 2021 ended September 30, 2020.

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for SB11, a proposed biosimilar referencing Lucentis®.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that three poster presentations will feature the company’s new silicone hydrogel daily disposable contact lens, Bausch + Lomb INFUSE™, during the virtual American Academy of Optometry Annual Meeting.

Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 39,000 shares of its common stock to three new employees and the grant of 22,500 restricted stock units to two of the three new employees.

Independent Data Monitoring Committee (IDMC) conducted a pre-planned interim analysis of the Company’s Phase III Comfort™ trial of Piclidenoson for the treatment of psoriasis and recommended to continue with this psoriasis study A separate IDMC for the pre-planned interim analysis of the Acrobat™ Rheumatoid Arthritis (RA) Phase III study recommended not to continue this study. The Company plans to undertake a detailed analysis of the data of the

GT Biopharma, Inc. (OTCQB:GTBP) announced today that it had entered into a partnership agreement with Cytovance Biologics, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”).

Protech Home Medical Corp. (“Protech” or the “Company”) (TSXV: PTQ), (OTCQX: PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is pleased to announce that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th – 16th, 2020.